Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2008-07-29
2008-07-29
Kemmerer, Elizabeth C. (Department: 1649)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C436S501000, C436S503000
Reexamination Certificate
active
10511758
ABSTRACT:
Method for early diagnosis and diagnosis, for prognosis and assessment of the severity and for therapy-accompanying monitoring of inflammatory diseases and infections, in particular sepsis-like systemic infections and Alzheimer's disease, in which the presence and/or amount of the protein LASP-1 (SEQ ID NO:1) or of the protein LAP-1 (SEQ ID NO:16) or of an immunoreactive fragment of one of these proteins in free and/or protein-bound form is determined, preferably as immunoreactivity, in a biological fluid, or optionally a tissue sample, of a patient, and conclusions are drawn with respect to the presence, the expected course, the severity or the success of a therapy of the inflammatory disease or of the infection from the presence and/or amount of the proteins determined.
REFERENCES:
patent: 4822733 (1989-04-01), Morrison
patent: 5512493 (1996-04-01), Mathis et al.
patent: 5639617 (1997-06-01), Bohuon
patent: 5981218 (1999-11-01), Rio et al.
patent: 6743619 (2004-06-01), Tang et al.
patent: 6756483 (2004-06-01), Bergmann
patent: 6919193 (2005-07-01), Tang et al.
patent: 7132246 (2006-11-01), Bergmann et al.
patent: 7157081 (2007-01-01), Bergmann et al.
patent: 2005/0059104 (2005-03-01), Bergmann et al.
patent: 2005/0064506 (2005-03-01), Bergmann et al.
patent: 2005/0074811 (2005-04-01), Bergmann et al.
patent: 2005/0106645 (2005-05-01), Bergmann et al.
patent: 2005/0239150 (2005-10-01), Bergmann et al.
patent: 2006/0035221 (2006-02-01), Bergmann et al.
patent: 2006/0115869 (2006-06-01), Bergmann et al.
patent: 2006/0234295 (2006-10-01), Bergmann et al.
patent: 42 27 454 (1994-03-01), None
patent: 198 47 690 (2000-04-01), None
patent: 199 15 485 (2000-10-01), None
patent: 0 539 477 (1995-08-01), None
patent: 0 656 121 (1998-04-01), None
patent: WO 92/10200 (1992-06-01), None
patent: WO 98/27213 (1998-06-01), None
patent: WO 00/22439 (2000-04-01), None
patent: WO 01/25268 (2001-04-01), None
patent: WO 01/36975 (2001-05-01), None
patent: WO 01/85986 (2001-11-01), None
patent: WO 01/86288 (2001-11-01), None
patent: WO 02/00857 (2002-01-01), None
patent: WO 02/10771 (2002-02-01), None
Richard Mayeux, NeuroRx. 2004; 1: 182-188.
Bork, 2000, Genome Research 10:398-400.
Skolnick et al., 2000, Trends in Biotech. 18(1):34-39.
Doerks et al., 1998, Trends in Genetics 14:248-250.
Smith et al., 1997, Nature Biotechnology 15:1222-1223.
Brenner, 1999, Trends in Genetics 15:132-133.
Bork et al., 1996, Trends in Genetics 12:425-427.
Dayer et al., Nat Clin Pract Rheumatol. 2007; 3: 512-20.
Gabay, C. et al., “Acute-Phase Proteins and Other Systemic Responses to Inflammation,”The New England Journal of Medicine, vol. 340, No. 6 (Feb. 11, 1999) pp. 448-454.
Assicot, M. et al., “High serum procalcitonin concentrations in patients with sepsis and infection,”The Lancet, vol. 341, No. 8844 (Feb. 27, 1993) pp. 515-518.
Karzai, W. et al., “Procalcitonin—A New Indicator of the Systemic Response to Severe Infections,”Infection, vol. 25, No. 6 (Nov. 1997) pp. 329-334.
Oczenski, W. et al., “Procalcitonin: a new parameter for the diagnosis of bacterial infection in the peri-operative period,”European Journal of Anaesthesiology, vol. 15 (1998) pp. 202-209.
Redl, H. et al., “Procalcitonin release patterns in a baboon model of trauma and sepsis: Relationship to cytokines and neopterin,”Crit Care Med, vol. 28, No. 11 (2000) pp. 3659-3663.
Redl, H. et al., “Non-Human Primate Models of Sepsis,”Sepsis, vol. 2 (1998) pp. 243-253.
Panacek, E., “Anti-TNF strategies,”Journal für Anästhesie(2001) pp. 4-5.
Calandra, T. et al., “Protection from septic shock by neutralization of macrophage migration inhibitory factor,”Nature Medicine, vol. 6, No. 2 (Feb. 2000) pp. 164-170.
Garber, K., “Protein C may be sepsis solution,”Nature Biotechnology, vol. 18 (Sep. 2000) pp. 917-918.
Chew, C. et al., “Lasp-1 is a regulated phosphoprotein within the cAMP signaling pathway in the gastric parietal cell,”The American Psychological Society, vol. 275 (1998) pp. 56-67.
Tomasetto, C. et al., “Lasp-1 (MLN 50) defines a new LIM protein subfamily characterized by the association of LIM and SH3 domains,”FEBS Letters, vol. 373 (1995) pp. 245-249.
Tomasetto, C. et al., “Identification of Four Novel Human Genes Amplified and Overexpressed in Breast Carcinoma and Localized to the q11-q21.3 Region of Chromosome 17,”Genomics, vol. 28 (1995) pp. 367-376.
Lue, L. et al., “Inflammatory Repertoire of Alzheimer's Disease and Nondemented Elderly Microglia In Vitro,”GLIA, vol. 35 (2001) pp. 72-79.
Hüll, M. et al., “Anti-inflammatory substances—a new therapeutic option in Alzheimer's disease,”DDT, vol. 4, No. 6 (Jun. 1999) pp. 275-282.
Licastro, F. et al., “Increased plasma levels of interleukin-1, interleukin-6 and α-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain?,”Journal of Neuroimmunology, vol. 103 (2002) pp. 97-102.
Akiyama, H. et al., “Inflammation and Alzheimer's disease,”Neurobiology of Aging, vol. 21 (2000) pp. 383-421.
Hüll, M. et al., “Anti-inflammatory drugs: a hope for Alzheimer's disease?,”Exp. Opin. Invest. Drugs, vol. 9, No. 4 (2002) pp. 671-683.
Hüll, M. et al., “Inflammatory mechanisms in Alzheimer's disease,”Eur Arch Psychiatry Clin Neurosci, vol. 246 (1996) pp. 124-128.
Rhodin, J. et al., “Animal Model of Alzheimer-like Vascular Pathology and Inflammatory Reaction,”Annals New York Academy of Sciences, pp. 345-352.
Schreiber, V. et al., “Lasp-1, a Novel Type of Actin-Binding Protein Accumulating in Cell Membrane Extensions,”Molecular Medicine, vol. 4 (1998) pp. 675-687.
Ghillani, P. et al., “Monoclonal Antipeptide Antibodies as Tools to Dissect Closely Related Gene Products,”The Journal of Immunology, vol. 141, No. 9 (Nov. 1, 1998) pp. 3156-3163.
Ghillani, P. et al., “Identification and Measurement of Calcitonin Precursors in Serum of Patients with Malignant Diseases,”Cancer Research, vol. 49, No. 23 (Dec. 1, 1989) pp. 6845-6851.
Otto, A. et al., “Identification of human myocardial proteins separated by two-dimensional electrophoresis using an effective sample preparation for mass spectometry,”Electrophoresis, vol. 17 (1996) pp. 1643-1650.
Neubauer, G. et al., “Mass spectrometry and EST-database searching allows characterization of the multi-protein spliceosome complex,”Nature Genetics, vol. 20 (Sep. 1998) pp. 46-50.
Lingner, J. et al., “Reverse Transcriptase Motifs in the Catalytic Subunit of Telomerase,”Science, vol. 276 (Apr. 25, 1997) pp. 561-567.
Mann, M. et al., “Use of mass spectrometry-derived data to annotate nucleotide and protein sequence databases,”TRENDS in Biochemical Sciences, vol. 26, No. 1 (Jan. 2001) pp. 54-61.
International Search Report for PCT/EP03/03946 dated Nov. 10, 2003.
Reinhart, K. et al., “Sepsis und septischer Schock,” Need Pub Name (2001) pp. 756-760.
Butt, E. et al., “Actin Binding of Human LIM and SH3 Protein Is Regulated by cGMP- and cAMP-dependent Protein Kinase Phosphorylation on Serine 146,”The Journal of Biological Chemistry, vol. 278, No. 18 (May 2, 2003) pp. 15601-15607.
Beishuizen, A. et al., “Endogenous Mediators in Sepsis and Septic Shock,”Advances in Clinical Chemistry, vol. 33 (1998) pp. 55-131.
Office Action dated Sep. 24, 2007 in co-pending U.S. Appl. No. 10/496,173.
Office Action dated Sep. 24, 2007 in co-pending U.S. Appl. No. 10/496,096.
Supplemental Notice of Allowability in co-pending U.S. Appl. No. 10/511,756.
Office Action dated Jun. 27, 2007 in co-pending U.S. Appl. No. 10/496,250.
Office Action dated Jan. 7, 2008 in co-pending U.S. Appl. No. 10/497,679.
Office Action dated Jan. 29, 2008 in co-pending U.S. Appl. No. 10/516,618.
Bergmann Andreas
Fischer-Schulz Christina
Struck Joachim
B.R.A.H.M.S. Aktiengesellschaft
Bell Charles E.
Borgeest Christina
Heslin Rothenberg Farley & & Mesiti P.C.
Kemmerer Elizabeth C.
LandOfFree
Method for diagnosing inflammatory diseases and infections... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for diagnosing inflammatory diseases and infections..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for diagnosing inflammatory diseases and infections... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3918187